Kornimate/medical-research-clean huggingface dataset:
covid-19 in rheumatic inflammatory diseases under immuno-suppressive drugs

Conditions: Chronic Inflammatory Rheumatism

Summary: accurate knowledge of the humoral immune responses induced by sars-cov-2 in patients undergoing immunosuppressive therapy is essential to guide recommendations for infected patients and for vaccination policy for uninfected immunosuppressed patients.

longitudinal, cas-control study, observational multicenter study based on a cohort of 200 sars-cov-2 seropositive patients with chronic inflammatory rheumatisms (cirs) from the covid-ric-1 cohort. the follow-up the persistence of sars-cov-2 serological status for 2 years in 200 patients with inflammatory rheumatisms compared to matched 100 healthy controls to evaluate the impact of immuno-suppressive therapy will be proposed. schedule: 4 visits over a 24-month period. an observational routine care study was initiated in 16 french hospitals to assess the sars-cov-2 seroprevalence in france in a population with cirs (covid-ric-1). the project plans to screen 5000 cirs patients. the covid-ric-2 study will thus be proposed to these pre-screened subjects according to their positive status in the serology for sars-cov-2 at the time of their inclusion in covid-ric-1. for the control group, 100 health professionals participating in the covid-biotoul cohort will be selected to be matched on age, gender, and the time between the date of infection with covid-19 and the first serology of cir patients.

Eligibility criteria:
inclusion criteria: * patients with rheumatoid arthritis or spondyloarthritis * with positive serology for sars-cov-2 infection less than 3 months old at the time of inclusion * under biotherapy, or conventional synthetic disease-modifying antirheumatic drugs (csdmard) or nonsteroidal anti-inflammatory drugs (nsaids) or steroids for at least one month during the year 2020 * agreeement to participate two years in the study exclusion criteria: * pregnant or breastfeeding woman * refusal to participate in the study

Keywords: covid-19 sars-cov2 rheumatoid arthritis spondyloarthritis seroprevalence seropersistence
carbetocin versus syntocinon for prevention of postpartum hemorrhage in cardiac patients undergoing caesarean section

Conditions: Adverse Effect of Oxytocic Drugs

Summary: postpartum hemorrhage (pph) is the primary cause of nearly one quarter of all maternal deaths globally. management of uterine tone after delivery involves giving a prophylactic uterotonic and the use of controlled cord traction to facilitate delivery of the placenta and minimize blood loss. syntocinon and carbetocin are the most commonly used drugs ,during caesarean delivery of stenotic valvular disease patient, the anesthesiologist have an important question: what is the best drug used for prevention of pph with minimal hemodynamic effect regarding systemic vascular resistance (svr), cardiac out put (cop),heart rate ( hr), blood pressure? as uterotonic drugs may cause severe hypotension, decrease in svr and cop that may not be tolerated by these patients .this thesis aims to compare between syntocinon and carbetocin regarding their effect on cardiac output and systemic vascular resistance using cardiometry in cardiac patients with stenotic lesions during caesarean delivery.


Eligibility criteria:
inclusion criteria: * pregnant female single tone \>38 weeks * age :18-45 years old. * patient with asa iii * cardiac patients ( mild and moderate mitral stenosis-aortic stenosis valve disease ) exclusion criteria: * other cardiac conditions (valve regurge, cardiomyopathy, heart failure,severe mitral stenosis, severe aortic stenosis, severe pulmonary hypertension) * pregnancy hypertensive disorders (eclampsia,preeclampsia) * abnormal placental attachment (accrete,percreta,increta) * patients with bleeding disorders * patient with high risk of postpartum haemorrhage
the effects of home monitors used with home oxygen therapy

Conditions: Frequency of Adverse Events, Health Care Utilization, Infant Growth, Parental Quality of Life, and Altitude of the Participant's Home

Summary: this study\&#39;s purpose is to determine the effects of using monitors with home oxygen therapy (hot). this trial will test the hypothesis that infants discharged from the neonatal intensive care unit (nicu) with hot will have a shorter treatment duration if used in conjunction with monitors.

this will be a randomized control trial in which infants being discharged from the neonatal intensive care unit with home oxygen therapy will be placed in one of two groups. those randomized into the treatment group will be sent home with a monitor to be used continuously during their need for supplemental oxygen. the control group will consist of infants randomized to receive the current standard of care, which is discharge with home oxygen and no home monitor. the research team will contact the families of the subjects at one-month intervals to collect pertinent data. aim 1: subjects will be randomly assigned to a control group (no home monitors, which is current clinical practice) and an experimental group (home monitors). the investigators will compare the duration of treatment with hot between groups. aim 2: obtain additional data from study participants to better understand the impact of home monitoring. this data includes frequency of adverse events (defined later in the protocol) including health care utilization, as well as parental quality of life, and altitude of the participant\&#39;s home. exploratory aim 1: determine the perceptions of families regarding home monitor use.

Eligibility criteria:
inclusion criteria: * • infants being discharged with home oxygen therapy. * infants born at other institutions and then transferred to unmh will be eligible if discharged home with home oxygen therapy. * infants born at gestational age 28 0/7 weeks or greater. * infants of employees of the unmh will be allowed to participate in the study but will not be targeted. all efforts will be made to ensure that no coercion or undue influence will be used in recruiting this population. exclusion criteria: * • infants diagnosed with conditions that will predispose them to prolonged hypoxemia; examples include cardiac anomaly, anatomic anomalies affecting the airway, tracheostomy dependency, cystic fibrosis, and trisomy 21. * infants discharged with hospice care / palliative services. * infants discharged greater than 6 months after they were born. * parents less than 18 years old or prisoners. * parents who are unable to provide consent due to having a legal representative. * infants who are in foster care and/or are wards of the state. * families not fluent in english.

Keywords: home oxygen monitors
locoregional therapy combined with bevacizumab and pd1/l1 inhibitor in advanced hepatocellular carcinoma

Conditions: Advanced Hepatocellular Carcinoma; Anti-PD1/PDL1 Antibody; Bevacizumab

Summary: atezolizumab + bevacizumab was superior to sorafenib in overall survival in advanced hepatocellular carcinoma. the programmed cell death protein-1 (pd1) and pdl1 inhibitor, was effective and tolerable in patients with advanced hepatocellular carcinoma. we aimed to describe the efficacy and safety of locoregional therapy combined with bevacizumab and pd1/l1 inhibitor in patients with advanced hepatocellular carcinoma who can not receive radical therapy.

this study is a multicenter, observational real-world study to explore the efficacy, safety of locoregional therapy combined with bevacizumab and pd1/l1 inhibitor in advanced hepatocellular carcinoma. this study focused on the management of locoregional therapy combined with bevacizumab and pd-1/l1 inhibitor. this study will create a database that will provide clinical parameters and outcomes of patients undergoing locoregional therapy combined bevacizumab and pd-1/l1 inhibitor as standard of care in hopes of answering key clinical questions.

Eligibility criteria:
inclusion criteria: 1. hcc diagnosed by histopathological examination or guidelines for diagnosis and treatment of primary liver cancer or the recurrent hcc after surgery; 2. age between 18 and 75 years; 3. stage b (middle stage) or c (late stage) hcc determined in accordance with barcelona clinic liver cancer staging system (bclc stage). 4. locoregional therapy include tace or haic, locoregional combined with bevacizumab and pd1/l1 inhibitor as firstline therapy; non-firstline therapy (previous use of any systemic therapy but intolerant or drug resistant). 5. child-pugh class a or b; 6. eastern cooperative group performance status (ecog) score of 0-2; 7. hemoglobin ≥ 8.5 g/dl total bilirubin ≤ 30mmol/l serum albumin ≥ 32 g/l asl and ast ≤ 5 x upper limit of normal serum creatinine ≤ 1.5 x upper limit of normal inr ≤ 1.5 or pt/aptt within normal limits absolute neutrophil count (anc) \>1,500/mm3 8. prothrombin time ≤18s or international normalized ratio \< 1.7. 9. ability to understand the protocol and to agree to and sign a written informed consent document. exclusion criteria: 1. cholangiocellular carcinoma (icc). 2. patients without image information should be excluded; 3. the survival or patients less than 3 months. 4. serious medical comorbidities. 5. evidence of hepatic decompensation including ascites, gastrointestinal bleeding or hepatic encephalopathy. 6. known history of hiv. 7. history of organ allograft. 8. known or suspected allergy to the investigational agents or any agent given in association with this trial. 9. cardiac ventricular arrhythmias requiring anti-arrhythmic therapy. 10. evidence of bleeding diathesis. 11. patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry.

Keywords: bevacizumab atezolizumab tislelizumab toripalimab sintilimab camrelizumab
genetic predisposition testing program for pancreatic neuroendocrine neoplasms

Conditions: Pancreatic Neuroendocrine Neoplasm

Summary: this is a prospective observational multi-center pilot study of germline testing for participants receiving care at university of california participating locations with a new or existing diagnosis of pancreatic neuroendocrine neoplasms (pannen). this protocol is an extension of existing genetic testing station efforts at university of california, san francisco (ucsf)

primary objective: i. to assess the frequency of germline mutations in patients with pannen. secondary objectives: i. to assess the rates of different types of germline mutations in patients pannen. ii. to assess the rates of different types of variants of uncertain significance in patients with pannen. iii. to estimate the rate of completion of genetic testing in patients who are offered prospective germline testing. exploratory objectives: i. to examine attitudes of patients who have completed germline testing. ii. to explore reasons for declining germline testing. iii. in patients with repeat germline testing, compare the frequency of germline alteration between tests. iv. assess the relationship between germline pathogenic variants and somatic mutations in pannen. outline: potential eligible participants will be identified via chart review and invited to consent to the study. study participants who agree to prospective testing and have not had previous large panel germline testing will watch an informational video about germline testing and be offered testing with university of california, san francisco's (ucsf) expanded hereditary cancer panel. study participants who decline germline testing will be asked to answer a one-question declination survey. results will be shared with participants and their providers per the standard of practice at each participating study site. all participants who decided to receive germline testing will be asked to complete a decision survey.

Eligibility criteria:
inclusion criteria: 1. histologically confirmed pannen. a. the diagnostic biopsy may have been taken from any site (primary or metastatic). 2. new and existing pannen participants will be eligible (any grade, any stage, any age \> 18 years). 3. participants willing and able to comply with the study procedures. exclusion criteria: 1. inability to provide informed consent. 2. for participants who have not had prior testing with a dedicated germline pane of at least 80 genes: 1. inability to speak/read a language supported by the germline testing station (gts). the supported languages currently include english, korean, japanese, vietnamese, russian, tagalog, farsi, spanish, cantonese, mandarin, and arabic). 2. active hematologic malignancy. 3. history of allogenic bone marrow transplant or stem cell transplant.

Keywords: genetic assay biomarkers
oral health-related quality of life between two different types of orthodontic appliances

Conditions: Crowding of Anterior Mandibular Teeth

Summary: patients who have mild crowding from the orthodontic department at university of damascus dental school will be treated in this trial. the effects of modified aligner appliance with niti springs on oral health-related quality of life (ohrqol) compared with conventional fixed appliances using the ohip-14 questionnaire during orthodontic treatment. so, this study aims to compare the changes in ohrqol between patients receiving modified aligner appliances or conventional fixed appliances during orthodontic treatment. there are two groups: 1. experimental group: the patients in this group will be treated using a modified aligner appliance. 2. control group: the patients in this group will be treated using conventional fixed appliances

most adult patients do not choose traditional fixed appliances due to concerns about appearance, lengthy treatment time, and challenges with oral hygiene. this study aimed to assess the impact on psychological well-being, aesthetics, and functionality of a novel single aligner appliance.

Eligibility criteria:
inclusion criteria: 1. patients aged between (18 - 25) years. 2. mild crowding \< 4 mm in the lower dental arch with class i malocclusion 3. no congenitally missing or extracted teeth (except for third molars) 4. patients with good oral hygiene. exclusion criteria: 1. bimaxillary dentoalveolar protrusion. 2. previous orthodontic treatment. 3. severe skeletal discrepancy.
treatment of rheumatoid arthritis with marine and botanical oils

Conditions: Rheumatoid Arthritis

Summary: the object of this study is to determine whether treatment of rheumatoid arthritis (ra) with a combination of fish oil and borage seed oil is superior to treatment with either oil alone. this study will also investigate the biochemical, immunological, and molecular mechanism responsible for the therapeutic effects of these fatty acids. each patient will be followed for eighteen months.

see brief summary

Eligibility criteria:
inclusion criteria * definite ra with onset at \> 16 years, with total disease duration of at least 6 months * active disease as manifested by at least 3 joints that are swollen and 6 joints that are tender at time of enrollment, and either an erythrocyte sedimentation rate \>_28, or a crp \>1.4, or morning stiffness of at least 45 min * stable dose of dmards for 2 mos before baseline visit, with total duration of dmard for 6 mos. * all standard therapy for ra, including dmards and combinations of dmards will be allowed as long as doses have been stable for 2 mos * stable nsaid for 1 month before baseline if on an nsaid * stable prednisone dose of \< 10 mg/day for 1 month before baseline visit, if on prednisone * ability to give and understand all elements of informed consent * absence of comorbid condition which, in the opinion of the physician-investigator, would render the patient unsuitable for the study * willingness to adhere to the clinical protocol. exclusion criteria * a diagnosis of inflammatory arthritis other than rheumatoid arthritis * chronic anticoagulation * hypersensitivity to fish or fish products or plant products * a dose of prednisone of \> 10 mg/day, or either a change in the prednisone dose or intra-articular corticosteroid injection within one month of the baseline evaluation * an inability or unwillingness to use an effective form of contraception (females) during the duration of the study * pregnant and breast-feeding females * inability or unwillingness to adhere to the study diet * platelet count \< 100,000/mm 3 * hemoglobin \< 9 g/dl * albumin \< 3.3 g

Keywords: fish oil borage oil
trastuzumab-radiotherapy : impact on the cerebral prevention

Conditions: Breast Cancer; Metastasis; Sur-expressing Her2-neu

Summary: evaluate the survival without metastasis in patients treated by trastuzumab in association with other chemotherapies for a breast cancer expressing her2-neu.


Eligibility criteria:
inclusion criteria: * patients with breast cancer, expressing her2-neu (score +++ in ich or ++ and amplification on fish or cish, sish) * visceral metastasis, only or multiple * first line metastasis treatment by trastuzumab in association with chemotherapy * good general conditions: oms=\ =70% * age \> 18 years and \< 70 years * life expectancy \>=3 mois * no trastuzumab since more of 6 months * no cerebral metastasis (mri) * efficacy contraception for women with genital capacities * consent signed by the patient exclusion criteria * contraindication to irm * psychiatric decease * prior cerebral radiotherapy, * geographical constraint, compromising the fallow of patients * infectious or other serious pathology, likely to stop the treatment * positive serology (hiv, hbc, hbs) * inclusion in an other clinical trial or in the 4 weeks before th inclusion * pregnant or breastfeeding women
psychedelics and wellness study (paws)

Conditions: Depression, Anxiety, PTSD

Summary: the psychedelics and wellness study (paws), is an anonymous online survey investigating the interrelationship between psychedelics and wellness. the study population is adults ages 18 and older that have taken a psychedelic at least once. the maximum sample size is 5,000 survey respondents. it is expected that this anonymous online survey will support the hypothesis that there is a robust interrelationship between past psychedelic use and its impact on wellness.

following a four-decade moratorium, the therapeutic use of psychedelics has once more captured the collective attention of the medical community and the public at large. now, at the forefront of a renaissance in psychedelic research, this study is investigating the interrelationship of psychedelics and mental wellness - a state of well-being in which the individual realizes his or her own abilities, can cope with the normal stresses of life, can work productively and fruitfully, and is able to make a contribution to his or her community. this work will be unique in that it will collect both objective and subjective data to assess the interrelationship between psychedelic and wellness. it will lend support to the growing body of research in the use of psychedelics for both mental health conditions and the pursuit of overall mental wellness.

Eligibility criteria:
inclusion criteria: * adults ages 18 and older that have taken a psychedelic at least once. exclusion criteria: * individuals less than 18 years old and have previously never taken a psychedelic substance.

Keywords: psychedelics, wellness
the effect of sod enzyme on frailty and hrqol among indonesian pre-frail elderly: a double blind randomized controlled trial

Conditions: Pre-frail Elderly

Summary: the primary objective is to determine the effect of sod enzyme on frailty and health related quality of life among indonesian pre-frail elderly. the secondary objective is to determine the effect of sod enzyme on anti-oxidant status, morbidity, and hospitalization among indonesian pre-frail elderly. the study hypothesis: 1. sod enzyme can improve frailty status and health related quality of life among indonesian pre-frail elderly. 2. sod enzyme can increase anti-oxidant serum status among indonesian pre-frail elderly. 3. sod enzyme can decrease morbidity among indonesian pre-frail elderly. 4. sod enzyme can decrease hospitalization events among indonesian pre-frail elderly.

1. study design: randomized double blind placebo controlled trial. 2. location and time of study: geriatric outpatient clinic and internal medicine outpatient clinic in cipto mangunkusumo national hospital jakarta. study will be conducted on april 2016 to april 2017. 3. study subject: elderly outpatient (aged 60 years old or more) with pre-frail status, who visit the clinic for medical consultation. 4. data sampling: consecutive method. 5. sample size: 150 subjects (75 control group, 75 intervention group). 6. data collection: demographic data, frailty status, health related quality of life, anthropometric data, anti-oxidant serum status, hospitalization during intervention, morbidity, nutritional status, food intake, hand grip strength. 7. intervention: sod+gliadin in capsule with a dose of 250 mg twice a day for 24 weeks will be given to intervention group, while placebo group will be given placebo capsule (amylum).

Eligibility criteria:
inclusion criteria: * elderly aged 60 years or more with pre-frail condition * patients with sod enzyme deficiency * willing to participate exclusion criteria: * patients with cognitive function impairment (amt score \< 8) * patients with depression (geriatric depression scale score \>= 10) * patients with history of cirrhotic hepatic disease or severe hepatic disease * patients with kidney function impairment * patients with gluten allergy and derivative products * patients consume other antioxidant and omega-3 supplement

Keywords: elderly, pre-frail, sod
anaesthesia with propofol versus midazolam : effect on oxidative stress in the brain of head trauma patients

Conditions: Traumatic Brain Injury

Summary: severe traumatic brain injury is associated with an increased production of free radicals causing brain damage. first line treatment of these patients aims to maintain cerebral perfusion and includes deep anaesthesia. propofol has recently shown anti oxidant properties that need to be confirmed when used in these patients. the main objective of this study is to evaluate the effect of propofol compared to midazolam on intra cerebral oxidative stress following severe traumatic brain injury.

severe traumatic brain injury is associated with an increased production of free radicals causing brain damage. first line treatment of these patients aims to maintain cerebral perfusion and includes deep anaesthesia. propofol has recently shown anti oxidant properties that need to be confirmed when used in these patients. the main objective of this study is to evaluate the effect of propofol compared to midazolam on intra cerebral oxidative stress following severe traumatic brain injury. measurements will be performed by use of intracerebral microdialysis.

Eligibility criteria:
inclusion criteria: age≥18 years, severe traumatic brain injury with a glasgow coma scale ≤8 related to the trauma, stage ii, iii or iv of the us trauma data bank on the ct scan, need for intracranial pressure monitoring, written informed consent from the patient's next-of-kin. if no relative is present as the time of inclusion, the patients will be included according to the emergency procedure. non-inclusion criteria: traumatic brain injury requiring urgent neurosurgical intervention due to blood collection, contraindication to propofol or midazolam, history of head trauma \> 12 hours before intra cranial pressure monitoring, patient receiving propofol by continuous infusion since head trauma.

Keywords: traumatic brain injury propofol oxidative stress microdialysis